Home | Osteal Therapeutics Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences
Osteal raises $50m to bring joint infection drug device combo . . . Osteal has designed VT-X7 for the treatment of periprosthetic joint infection The condition is a complication of joint replacement surgery in which bacteria infiltrate the joint implant This causes biofilms, a layer of microorganisms that are hard to treat
Osteal Therapeutics Announces Positive 12-Month Results Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences
Osteal secures $50m for joint infection drug device launch In summary, Osteal Therapeutics is on the cusp of significant advancements with its lead candidate, VT-X7, a novel treatment designed to address periprosthetic joint infections
Company | Osteal Therapeutics Osteal Therapeutics® is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences
News Events | Osteal Therapeutics Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences